Medifast Gains Zacks Rank #2, Sees 30.5% Earnings Growth Forecast
Medifast holds a Zacks Rank #2 (Buy) reflecting strong analyst sentiment despite missing average earnings estimates in each of the past four quarters. The Zacks Consensus Estimate foresees a 30.5% year-over-year earnings increase for the current financial year.
1. Zacks Ranking
Medifast currently holds a Zacks Rank #2 (Buy), signaling analysts’ positive outlook compared with other consumer staples names.
2. Earnings Surprises
The company has missed the average quarterly earnings surprise in each of the trailing four quarters, highlighting challenges in meeting consensus projections.
3. Consensus Estimate Growth
Analysts project a 30.5% year-over-year increase in Medifast’s earnings for the current financial year, driven by expected revenue growth and operational improvements.
Related News
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
BAC
Junk Debt Spreads Near 2007 Lows May Strain Bank Credit Portfolios
BAC•
XNDU
Xanadu Cuts QROM Toffoli Gate Count by 50% with New Algorithm
XNDU•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
Sources
F